Previous studies investigating the Japanese population showed that polypharmacy was an independent prognostic factor in older patients with advanced NSCLC treated with ICI or epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) [28, 29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.